Andreas Rimner, MD discusses a phase 3 clinical trial that is testing the addition of IMRT (intensity-modulated radiotherapy) to pemetrexed (Alimta)/platinum based therapy for pleural mesothelioma patients. Dr. Rimner also explained the difference between IMRT and proton therapy.
This study is open and enrolling pleural patients — the eligibility criteria are available here. Patients who need help with their diagnosis can contact Mary Hesdorffer, NP, the Foundation’s medical expert and executive director, on our website.
Dr. Rimner is a radiation oncologist specializing in mesothelioma and thoracic cancer at Memorial Sloan Kettering Cancer Center.
Watch MesoTV
MesoTV and all of its informational videos are possible with the generous support of our donors and sponsors. Importantly, during this difficult time we are able to continue serving, informing, and educating the mesothelioma community. Please take note of our Season 2 sponsors at the beginning of the video: Merck; The Gori Law Firm; Early, Lucarelli, Sweeney & Meisenkothen; and AstraZeneca.
Don’t miss any of our new videos – sign up to receive our news or subscribe to our YouTube Channel by pressing the red “Subscribe” button.
MesoTV is the Mesothelioma Applied Research Foundation’s recorded video series covering pertinent conversations impacting the mesothelioma community. You can learn more at curemeso.org/mesotv.
